Effects of testosterone replacement in middle-aged men with dysthymia: A randomized, placebo-controlled clinical trial

Journal of Clinical Psychopharmacology

Volumn 29, Issue 3, 2009, Pages 216-221

  Seidman, Stuart N ^a,b   Orr, Guy ^c   Raviv, Gil ^d,e   Levi, Rachel ^c   Roose, Steven P ^a,b   Kravitz, Efrat ^c,e   Amiaz, Revital ^c,e   Weiser, Mark ^c,e  

^a Columbia University ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c Department of Psychiatry ^*

^d SHEBA MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Andropause; Dysthymia; Hypogonadism; Male; Testosterone

Indexed keywords

PLACEBO; TESTOSTERONE; TESTOSTERONE ENANTATE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSTHYMIA; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL;

ADULT; AGED; ANDROGENS; DOUBLE-BLIND METHOD; DYSTHYMIC DISORDER; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TESTOSTERONE; TREATMENT OUTCOME;

EID: 67649274349     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a39137     Document Type: Article

References (52)

1. Beekman AT, Deeg DJ, Smit JH, et al. Dysthymia in later life: a study in the community. J Affect Disord. 2004;81:191-199.
2. Steffens DC, Skoog I, Norton MC, et al. Prevalence of depression and its treatment in an elderly population: the Cache County study. Arch Gen Psychiatry. 2000;57:601-607.
3. Costa E, Barreto SM, Uchoa E, et al. Prevalence of International Classification of Diseases, 10th Revision common mental disorders in the elderly in a Brazilian community: the Bambui Health Ageing Study. Am J Geriatr Psychiatry. 2007;15:17-27.
4. Devanand DP, Nobler MS, Singer T, et al. Is dysthymia a different disorder in the elderly? Am J Psychiatry. 1994;151:1592-1599.
5. Kocsis JH. Geriatric dysthymia. J Clin Psychiatry. 1998;59(suppl 10):13-15.
6. Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006;163:1493-1501.
7. Bartels SJ, Dums AR, Oxman TE, et al. Evidence-based practices in geriatric mental health care. Psychiatr Serv. 2002;53:1419-1431.
8. Baune BT, Adrian I, Arolt V, et al. Associations between major depression, bipolar disorders, dysthymia and cardiovascular diseases in the general adult population. Psychother Psychosom. 2006;75:319-326.
9. Seidman SN. Neuroendocrinology of mood disorders. In: Stein DJ, Schatzberg AF, Kupfer DJ, eds. Textbook of Mood Disorders. 1st ed. Washington, DC: American Psychiatric Press; 2005:117-130.
10. Seidman SN, Araujo AB, Roose SP, et al. Low testosterone levels in elderly men with dysthymic disorder. Am J Psychiatry. 2002;159:456-459.
11. Seidman SN. Testosterone deficiency and mood in aging men: pathogenic and therapeutic interactions. World J Biol Psychiatry. 2003;4:14-20.
12. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839-2853.
13. Anderson RA, Bancroft J, Wu FC. The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab. 1992;75:1503-1507.
14. Burris AS, Banks SM, Carter CS, et al. A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl. 1992;13:297-304.
15. Luisi M, Franchi F. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest. 1980;3:305-308.
16. McNicholas TA, Dean JD, Mulder H, et al. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91:69-74.
17. Steidle C, Schwartz S, Jacoby K, et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88:2673-2681.
18. Rinieris PM, Malliaras DE, Batrinos ML, et al. Testosterone treatment of depression in two patients with Klinefelter's syndrome. Am J Psychiatry. 1979;136:986-988.
19. Heuser I, Hartmann A, Oertel H. Androgen replacement in a 48, XXYY-male patient [Letter]. Arch Gen Psychiatry. 1999;56:194-195.
20. Ehrenreich H, Halaris A, Ruether E, et al. Psychoendocrine sequelae of chronic testosterone deficiency. J Psychiatr Res. 1999;33:379-387.
21. Seidman SN, Spatz E, Rizzo C, et al. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry. 2001;62:406-412.
22. Orengo CA, Fullerton L, Kunik ME. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J Geriatr Psychiatry Neurol. 2005;18:20-24.
23. Seidman SN, Rabkin JG. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord. 1998;48:157-161.
24. Pope HGJ, Cohane GH, Kanayama G, et al. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:105-111.
25. Seidman SN, Miyazaki M, Roose SP. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J Clin Psychopharmacol. 2005;25:584-588.
26. Rabkin JG, Wagner G, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57:141-147.
27. Ebinger M, Sievers C, Ivan D, et al. Is there a neuroendocrinological rationale for testosterone as a therapeutic option in depression? J Psychopharmacol. 2008 Jun 18 [Epub ahead of print].
28. Markianos M, Tripodianakis J, Sarantidis D, et al. Plasma testosterone and dehydroepiandrosterone sulfate in male and female patients with dysthymic disorder. J Affect Disord. 2007;101:255-258.
29. Shores MM, Sloan KL, Matsumoto AM, et al. Increased incidence of diagnosed depressive illness in hypogonadal older men. Arch Gen Psychiatry. 2004;61:162-167.
30. Almeida OP, Yeap BB, Hankey GJ, et al. Low free testosterone concentration as a potentially treatable cause of depressive symptoms in older men. Arch Gen Psychiatry. 2008;65:283-289.
31. Perry PJ, Yates WR, Williams RD, et al. Testosterone therapy in late-life major depression in males. J Clin Psychiatry. 2002;63:1096-1101.
32. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2:0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1995.
33. Rosen RC, Cappelleri JC, Gendrano N III. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226-244.
34. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542-1548.
35. Bandelow B, Baldwin DS, Dolberg OT, et al. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry. 2006;67:1428-1434.
36. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841-1853.
37. Khan A, Kolts RL, Thase ME, et al. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161:2045-2049.
38. Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr. 2004;9:808-821.
39. Rubin RT, Poland RE, Lesser IM. Neuroendocrine aspects of primary endogenous depression VIII. Pituitary-gonadal axis activity in male patients and matched control subjects. Psychoneuroendocrinology. 1989;14:217-229.
40. Kunelius P, Lukkarinen O, Hannuksela ML, et al. The effects of transdermal dihydrotestosterone in the aging male: a prospective, randomized, double blind study. J Clin Endocrinol Metab. 2002;87:1467-1472.
41. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-2098.
42. Schiavi RC, White D, Mandeli J, et al. Effect of testosterone administration on sexual behavior and mood in men with erectile dysfunction. Arch Sex Behav. 1997;26:231-241.
43. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997;82:1661-1667.
44. Tricker R, Casaburi R, Storer TW, et al. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men - a clinical research center study. J Clin Endocrinol Metab. 1996;81:3754-3758.
45. Benkert O, Witt W, Adam W, et al. Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. Arch Sex Behav. 1979;8:471-479.
46. Pope HGJ, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. A randomized controlled trial. Arch Gen Psychiatry. 2000;57:133-140.
47. Pope HGJ, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch Gen Psychiatry. 1994;51:375-382.
48. Daly RC, Su TP, Schmidt PJ, et al. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology. 2003;28:317-331.
49. Perry PJ, Kutscher EC, Lund BC, et al. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J Forensic Sci. 2003;48:646-651.
50. Altschule MD, Tillotson KJ. The use of testosterone in the treatment of depressions. N Engl J Med. 1948;239:1036-1038.
51. Kanayama G, Amiaz R, Seidman S, et al. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp Clin Psychopharmacol. 2007;15:529-538.
52. Bloch M, Schmidt PJ, Danaceau MA, et al. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry. 1999;45:1533-1541.